Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant RT + Androgen Suppression + Docetaxel for High Risk Prostate Cancer Post-Prostatectomy
NCT00528866Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Apr 2008
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by NRG Oncology. Primary endpoint: Number of Participants Free From Progression at 3 years. Started Apr 2008; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00528866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528866.